ACOS accounts for approximately 15 - 25% of the obstructive airway diseases with many patients experiencing worse outcomes compared with asthma or COPD alone, including acute exacerbations with higher frequency and greater severity. However, due to strict inclusion and exclusion criteria that exclude either asthma patients from COPD studies or COPD patients from asthma studies, the asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been poorly recognised.*
Hear more on applying current knowledge to clinical practice and the future of ACOS at SMi's 7th annual COPD show in a keynote address by Novartis Medical Director, Konstantinos Kostikas. The presentation will define the characteristics of what is commonly referred to as the "grey-zone syndrome" with a focus on clinical trials and unmet needs.
Other featured speakers at COPD 2015 include:
- Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG
- Philip Silkoff, Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC
- Stefano Petruzzelli, Chief Medical Officer and Director, Global Clinical Development, Chiesi Farmaceutici S.p.A
- Sanjeeva Dissanayake, Head of Medical Sciences - Respiratory, Mundipharma
- Geoff Down, Chief Medical Officer, Prosonix
- Thomas Schlange, Senior Biomarker Expert, Bayer
- Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune
Visit the website to see the full speaker line-up and agenda for 2015.
For those who are interested in attending there is currently a £400 early bird rate available expiring today. For more information or to register visit www.copd-conference.co.uk
Sponsored by Quintiles